The US FDA Approves BeiGene’s Label Update for Brukinsa to Include Chronic Lymphocytic Leukemia
Shots:
- The label expansion was based on the results from the P-III (ALPINE) clinical trial evaluating the safety & efficacy of Brukinsa vs Imbruvica in patients previously treated with r/r chronic lymphocytic leukemia (CLL)
- With a median follow-up of 31mos. the study depicted a superior PFS & demonstrated a favorable cardiac safety profile with significantly lower rates of atrial fibrillation/flutter (5.2% vs 13.3%) & lower deaths (0 vs 6) in patients receiving Brukinsa vs Imbruvica
- These results were presented at the ASH 2023 & were presented in The New England Journal of Medicine. Brukinsa is a small molecule inhibitor of BTK designed to deliver complete and sustained inhibition of the BTK protein
Ref: BeiGene | Image: BeiGene
Related News:- BeiGene’s Brukinsa with Obinutuzumab Receives the EC’s Approval for the Treatment of Follicular Lymphoma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
